Liisi Laaniste
Seminars
Wednesday 18th February 2026
High-throughput Drug Perturbation in Patient-Derived Gliomaspheres Enables Patient Stratification
2:00 pm
- Value of deep genetic characterisation and functional genomics on low-passage patient-derived glioma tumorspheres
- Genetic biomarker identification and validation
- Rapid clinical impact of tumour precision targeting by clinical stage drugs
Wednesday 18th February 2026
Driving the Use of Biomarker-Based Enrollment in GBM trials to Accelerate Clinical Success & Improve Patient Outcomes
1:30 pm
- Addressing the lack of analysis of molecular data in current enrolment protocols for GBM trials
- Discussing strategies to incorporate biomarker-based enrolment given the rise of personalized therapies
- Establishing the efficacy of targeted treatments in recurrent GBM to accelerate the delivery of peronalized therapies
